KR20230124765A - 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도 - Google Patents

재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도 Download PDF

Info

Publication number
KR20230124765A
KR20230124765A KR1020237027741A KR20237027741A KR20230124765A KR 20230124765 A KR20230124765 A KR 20230124765A KR 1020237027741 A KR1020237027741 A KR 1020237027741A KR 20237027741 A KR20237027741 A KR 20237027741A KR 20230124765 A KR20230124765 A KR 20230124765A
Authority
KR
South Korea
Prior art keywords
inhibitors
group
incorporated
dianhydrogalactitol
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237027741A
Other languages
English (en)
Korean (ko)
Inventor
데니스 엠. 브라운
켄트 씨. 시
앤 스타이노
리차드 슈와르쯔
새레스 카네칼
하워드 에이. 써드 버리스
제프리 바차
윌리엄 가너
Original Assignee
델 마 파마슈티컬스
데니스 엠. 브라운
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 델 마 파마슈티컬스, 데니스 엠. 브라운 filed Critical 델 마 파마슈티컬스
Publication of KR20230124765A publication Critical patent/KR20230124765A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
KR1020237027741A 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도 Ceased KR20230124765A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361829739P 2013-05-31 2013-05-31
US61/829,739 2013-05-31
PCT/US2014/040461 WO2014194312A2 (en) 2013-05-31 2014-06-02 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor
KR1020227018071A KR20220080199A (ko) 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018071A Division KR20220080199A (ko) 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도

Publications (1)

Publication Number Publication Date
KR20230124765A true KR20230124765A (ko) 2023-08-25

Family

ID=51989551

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020237027741A Ceased KR20230124765A (ko) 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR1020217025060A Ceased KR20210100754A (ko) 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR1020157037286A Ceased KR20160065776A (ko) 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR1020227018071A Ceased KR20220080199A (ko) 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020217025060A Ceased KR20210100754A (ko) 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR1020157037286A Ceased KR20160065776A (ko) 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR1020227018071A Ceased KR20220080199A (ko) 2013-05-31 2014-06-02 재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도

Country Status (14)

Country Link
US (1) US11026914B2 (enExample)
EP (1) EP3003321A4 (enExample)
JP (3) JP2016520622A (enExample)
KR (4) KR20230124765A (enExample)
CN (1) CN105579044A (enExample)
AU (2) AU2014273911B2 (enExample)
BR (1) BR112015029989A2 (enExample)
CA (1) CA2914025C (enExample)
CL (1) CL2015003512A1 (enExample)
IL (1) IL242853B (enExample)
MX (1) MX382824B (enExample)
SG (1) SG11201509837QA (enExample)
TW (1) TW201536278A (enExample)
WO (1) WO2014194312A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067241A1 (en) * 2013-06-13 2016-03-10 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2016138542A1 (en) * 2015-02-28 2016-09-01 Cyprus Therapeutics, Inc. Methods for inhibiting tumors and drug resistance
US20190091195A1 (en) * 2015-09-10 2019-03-28 Del Mar Pharmaceuticals Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer
US20190016817A1 (en) * 2015-12-29 2019-01-17 Oncobiologics, Inc. Buffered formulations of bevacizumab
US20200062839A1 (en) * 2017-05-01 2020-02-27 Del Mar Pharmaceuticals (Bc) Ltd. Use of dianhydrogalactitol or analogs and derivatives in combination with vegf inhibitors to treat cancer
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
EA202090024A1 (ru) * 2017-06-12 2020-04-10 Станислав Р. Бурзинский Способы лечения лептоменингеального заболевания
CN116832020A (zh) 2017-09-11 2023-10-03 阿托萨治疗学公司 制备和使用内昔芬的方法
WO2019211708A1 (en) * 2018-05-04 2019-11-07 Kashiv Biosciences, Llc Stable pharmaceutical compositions of dianhydrogalactitol
CN109337884B9 (zh) * 2018-12-21 2021-10-29 中国农业科学院北京畜牧兽医研究所 一种丙酮酸激酶基因及其应用
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
KR102415193B1 (ko) 2020-04-16 2022-06-29 사회복지법인 삼성생명공익재단 벤즈브로마론을 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학 조성물
US20230212571A1 (en) * 2020-06-08 2023-07-06 Neonc Technologies, Inc. Compositions and methods for delivering polynucleotides
CN114796522A (zh) * 2022-01-06 2022-07-29 宁波大学 一种靶向线粒体放大氧化应激的新型抗肿瘤纳米药物
WO2024039764A2 (en) * 2022-08-17 2024-02-22 Ohio State Innovation Foundation Epitranscriptomic analysis of glioma
KR20250052523A (ko) 2023-10-11 2025-04-21 서울대학교병원 재발성 뇌 종양 진단, 예방 또는 치료에서의 cxcr-4의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785077A (en) 1986-05-05 1988-11-15 Scripps Clinic And Research Foundation Substantially pure cytotoxicity triggering factor
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5294430A (en) * 1988-09-12 1994-03-15 University Of Rochester Use of dithiocarbamates to treat myelosuppression
EP2605650A4 (en) * 2010-08-18 2014-05-21 Del Mar Pharmaceuticals COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYL DIANHYDROGALACTITOL
AU2013209394A1 (en) 2012-01-20 2014-08-28 Dennis Brown Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US9814693B2 (en) * 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies

Also Published As

Publication number Publication date
US20160158186A1 (en) 2016-06-09
CA2914025A1 (en) 2014-12-04
JP2020079259A (ja) 2020-05-28
JP2016520622A (ja) 2016-07-14
WO2014194312A3 (en) 2015-02-05
CA2914025C (en) 2023-03-07
WO2014194312A2 (en) 2014-12-04
TW201536278A (zh) 2015-10-01
MX2015016404A (es) 2016-09-28
AU2014273911B2 (en) 2019-09-19
AU2019283893A1 (en) 2020-01-23
AU2019283893B2 (en) 2022-03-24
SG11201509837QA (en) 2015-12-30
CN105579044A (zh) 2016-05-11
EP3003321A2 (en) 2016-04-13
CL2015003512A1 (es) 2016-09-09
KR20220080199A (ko) 2022-06-14
EP3003321A4 (en) 2017-01-18
IL242853B (en) 2022-03-01
MX382824B (es) 2025-03-13
KR20160065776A (ko) 2016-06-09
US11026914B2 (en) 2021-06-08
KR20210100754A (ko) 2021-08-17
AU2014273911A1 (en) 2016-01-07
BR112015029989A2 (pt) 2017-08-22
JP2022088616A (ja) 2022-06-14

Similar Documents

Publication Publication Date Title
AU2019283893B2 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
US12336993B2 (en) Therapeutic benefit of suboptimally administered chemical compounds
JP6280546B2 (ja) ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
US20150087687A1 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
HK1208365A1 (en) Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
JP2022174200A (ja) 医薬組成物
AU2019213388A1 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
HK1224581A1 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230816

Application number text: 1020227018071

Filing date: 20220527

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231113

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240201

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231113

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I